RE: This has much more to do with the drop27 Oct 2020 18:59
Well its good you can all be so confident as to dismiss the results as "crap". Laughable really. From July to now is not exactly slow. Imspex have some good backing including the NHS trust, and after this have put the tech potential firmly on the radar as a challenger to the PCR. The accuracy could increase significantly with more data, and investors will be quite literally throwing money at them hands over fist. This news would have certainly garnered some interest, no doubt about that as an 80% success rate for a very limited trial is a very good start!
So, Shaun. Should NCYT holders be concerned? lets put it this way, it would be rather foolish to dismiss this tech as "clickbait" and completely disregard it. Many countries worked on a PCR and still are, NCYT got the breakthrough and the best test to date. Many are working on a breath test, and with an 80% success rate in a very limited first trial shows it could have legs whether it be by imspex or someone else. Funding and scaling will happen at breakneck speed if it was as simple as blowing into a tube and get a result in 1 min. 95% accuracy would be good enough in airports purely for the simplicity and practicality. A 98%+ test would be truly revolutionary and render the PCR as virtually obsolete. So i think your answer of whether investors should be concerned is a little more complicated than "no", and any prudent investor would never dismiss such news. Judging by the selloff today, many didn't dismiss.
Besides, is it not good news that a new tech could potentially save lives? Anyone would think the way some are talking on here is that a groundbreaking new test would be a disaster.....